Filing Flows › Cirtran (CIRX) › Q1 2026 › vs Q4 2025
Cirtran (CIRX) Q1 2026 vs Q4 2025 (quarter over quarter)
Cirtran's revenue fell $888K (-43%) from $2.0M in Q4 2025 to $1.2M in Q1 2026. The biggest changes: Tobacco Line −$867K (-44%); All Other Product Line −$21K (-34%). Gross margin 39.9% against 49.2% (-9.3 pts).
Cirtran, Q1 2026: revenue $1.2M (+152% year over year), operating margin 3.1%, net earnings $2.2M, operating cash flow −$59K. The chart draws each line against Q4 2025, the increases inside each band.
Margins
| Q1 2026 | Q4 2025 | Change | |
|---|---|---|---|
| Gross margin | 39.9% | 49.2% | -9.3 pts |
| Operating margin | 3.1% | 13.3% | -10.2 pts |
| Net margin | 191.2% | 21.3% | +169.9 pts |
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Tobacco Line | $1.1M | $2.0M | −$867K | -44% |
| All Other Product Line | $41K | $62K | −$21K | -34% |
| Revenue | $1.2M | $2.0M | −$888K | -43% |
| Gross profit | $463K | $1.0M | −$544K | -54% |
| Cost of revenue | $698K | $1.0M | −$344K | -33% |
| Other income, net | $2.2M | $188K | $2.0M | 12× |
| Operating profit | $36K | $273K | −$237K | -87% |
| Operating expenses | $427K | $734K | −$307K | -42% |
| Pre-tax earnings | $2.2M | $461K | $1.8M | +381% |
| SG&A | $297K | $620K | −$323K | -52% |
| Other operating costs | $130K | $114K | $16K | +14% |
| Net earnings | $2.2M | $436K | $1.8M | +409% |
| Operating cash sources | $2.3M | $743K | $1.5M | +207% |
| Depreciation | $476 | $487 | −$11 | -2% |
| Cash used in operations | $59K | $306K | −$247K | -81% |
| Working capital & other | $2.3M | $743K | $1.5M | +207% |
Questions
How much did Cirtran's revenue grow quarter over quarter in Q1 2026?
Cirtran's revenue fell $888K (-43%) from $2.0M in Q4 2025 to $1.2M in Q1 2026.
What drove Cirtran's revenue change in Q1 2026?
Tobacco Line −$867K (-44%); All Other Product Line −$21K (-34%).